Certified by Founder Lodge
Abingworth
United Kingdom - London, UK
INVESTOR
1 Disclosed Funding Rounds $150,000,000
51 Participating Investments
-
Operating Status
Active
-
Last Funding Type
Seed
-
Company Type
For Profit
- Website
- Contact
- Social Links
Abingworth is a leading transatlantic life sciences investment firm. Abingworth helps transform cutting-edge science into novel medicines by providing capital and expertise to top caliber man
| Company | Date | Round | Raised |
|---|---|---|---|
 Glycomine Inc. |
April, 17 ,2025 | Series C | $115,000,000 |
 Iambic Therapeutics |
October, 06 ,2023 | Series B | $100,000,000 |
 Atsena Therapeutics |
April, 07 ,2025 | Series C | $150,000,000 |
 Scorpion Therapeutics |
July, 17 ,2024 | Series C | $150,000,000 |
 Myricx Bio |
July, 09 ,2024 | Series A | $115,246,800 |
 Antares Therapeutics |
June, 11 ,2025 | Series A | $117,000,000 |
 Addition Therapeutics |
December, 18 ,2025 | Unknown | $100,000,000 |
| Glycomine Inc. |
April, 17 ,2025 | Series C | $115,000,000 |
 Pathalys Pharma |
February, 07 ,2023 | Unknown | $150,000,000 |
| Atsena Therapeutics |
April, 07 ,2025 | Series C | $150,000,000 |
| Glycomine Inc. |
April, 17 ,2025 | Series C | $115,000,000 |
| Myricx Bio |
July, 09 ,2024 | Series A | $115,246,800 |
| Scorpion Therapeutics |
July, 17 ,2024 | Series C | $150,000,000 |
| Addition Therapeutics |
December, 18 ,2025 | Unknown | $100,000,000 |
 Ascend Gene & Cell Therapies |
May, 10 ,2023 | Series A | $132,500,000 |
| Pathalys Pharma |
February, 07 ,2023 | Unknown | $150,000,000 |
| Glycomine Inc. |
April, 17 ,2025 | Series C | $115,000,000 |
| Atsena Therapeutics |
April, 07 ,2025 | Series C | $150,000,000 |
| Scorpion Therapeutics |
July, 17 ,2024 | Series C | $150,000,000 |
| Iambic Therapeutics |
October, 06 ,2023 | Series B | $100,000,000 |
| Ascend Gene & Cell Therapies |
May, 10 ,2023 | Series A | $132,500,000 |
| Antares Therapeutics |
June, 11 ,2025 | Series A | $117,000,000 |
| Atsena Therapeutics |
April, 07 ,2025 | Series C | $150,000,000 |
| Glycomine Inc. |
April, 17 ,2025 | Series C | $115,000,000 |
| Iambic Therapeutics |
October, 06 ,2023 | Series B | $100,000,000 |
| Myricx Bio |
July, 09 ,2024 | Series A | $115,246,800 |
| Antares Therapeutics |
June, 11 ,2025 | Series A | $117,000,000 |
| Addition Therapeutics |
December, 18 ,2025 | Unknown | $100,000,000 |
| Glycomine Inc. |
April, 17 ,2025 | Series C | $115,000,000 |
| Antares Therapeutics |
June, 11 ,2025 | Series A | $117,000,000 |
| Addition Therapeutics |
December, 18 ,2025 | Unknown | $100,000,000 |
| Myricx Bio |
July, 09 ,2024 | Series A | $115,246,800 |
| Scorpion Therapeutics |
July, 17 ,2024 | Series C | $150,000,000 |
| Addition Therapeutics |
December, 18 ,2025 | Unknown | $100,000,000 |
 R1 Therapeutics |
March, 18 ,2026 | Series A | $77,500,000 |
| Antares Therapeutics |
June, 11 ,2025 | Series A | $117,000,000 |
| Addition Therapeutics |
December, 18 ,2025 | Unknown | $100,000,000 |
| Atsena Therapeutics |
April, 07 ,2025 | Series C | $150,000,000 |
| Scorpion Therapeutics |
July, 17 ,2024 | Series C | $150,000,000 |
| Glycomine Inc. |
April, 17 ,2025 | Series C | $115,000,000 |
| R1 Therapeutics |
March, 18 ,2026 | Series A | $77,500,000 |
| Antares Therapeutics |
June, 11 ,2025 | Series A | $117,000,000 |
| Atsena Therapeutics |
April, 07 ,2025 | Series C | $150,000,000 |
| Addition Therapeutics |
December, 18 ,2025 | Unknown | $100,000,000 |
| Glycomine Inc. |
April, 17 ,2025 | Series C | $115,000,000 |
| R1 Therapeutics |
March, 18 ,2026 | Series A | $77,500,000 |
| Antares Therapeutics |
June, 11 ,2025 | Series A | $117,000,000 |
 Cytospire Therapeutics Ltd |
May, 07 ,2026 | Series A | $82,984,705 |
| Addition Therapeutics |
December, 18 ,2025 | Unknown | $100,000,000 |
| R1 Therapeutics |
March, 18 ,2026 | Series A | $77,500,000 |
| Cytospire Therapeutics Ltd |
May, 07 ,2026 | Series A | $82,984,705 |
Cherry Ventures
Blue Bear Capital
Slow Ventures
Climate Capital
Eniac Ventures
Leadbay (YC F25) | $4,300,000 | (May 20, 2026)
Blank Bio | $7,200,000 | (May 20, 2026)
Benji | $6,250,000 | (May 20, 2026)
Vital Signals | $15,000,000 | (May 20, 2026)
Kin Health | $9,000,000 | (May 20, 2026)
